215 related articles for article (PubMed ID: 15542435)
1. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Mellinghoff IK; Vivanco I; Kwon A; Tran C; Wongvipat J; Sawyers CL
Cancer Cell; 2004 Nov; 6(5):517-27. PubMed ID: 15542435
[TBL] [Abstract][Full Text] [Related]
2. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
[TBL] [Abstract][Full Text] [Related]
3. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
Hsu FN; Yang MS; Lin E; Tseng CF; Lin H
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E902-8. PubMed ID: 21364123
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Mellinghoff IK; Tran C; Sawyers CL
Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
[TBL] [Abstract][Full Text] [Related]
6. HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
Freeman MR
Cancer Cell; 2004 Nov; 6(5):427-8. PubMed ID: 15542423
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
8. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.
Cinar B; De Benedetti A; Freeman MR
Cancer Res; 2005 Apr; 65(7):2547-53. PubMed ID: 15805247
[TBL] [Abstract][Full Text] [Related]
9. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.
Manin M; Baron S; Goossens K; Beaudoin C; Jean C; Veyssiere G; Verhoeven G; Morel L
Biochem J; 2002 Sep; 366(Pt 3):729-36. PubMed ID: 11971763
[TBL] [Abstract][Full Text] [Related]
11. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
12. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
Craft N; Shostak Y; Carey M; Sawyers CL
Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
[TBL] [Abstract][Full Text] [Related]
13. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H; Schmidt LJ; Tindall DJ
Cancer Res; 2001 Oct; 61(20):7408-12. PubMed ID: 11606371
[TBL] [Abstract][Full Text] [Related]
14. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
15. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
16. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
[TBL] [Abstract][Full Text] [Related]
18. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells.
Hassan S; Dobner PR; Carraway RE
Regul Pept; 2004 Aug; 120(1-3):155-66. PubMed ID: 15177934
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
20. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]